- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07937865
Early Intervention for Postpartum PTSD: Comparing Written Exposure and Capnometry-Guided Breathing Therapy - Phase 2
Early Intervention for Postpartum PTSD: Comparing Written Exposure and Capnometry Guided Breathing Therapy - Phase 2
The purpose of this study is to evaluate the feasibility, acceptability, and preliminary effectiveness of two early interventions, Written Exposure Therapy (WET) and Capnometry-Guided Breathing Intervention (CGRI), for reducing post-traumatic stress disorder (PTSD) symptoms following childbirth, compared with usual care.
Přehled studie
Postavení
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
Arkansas
-
Little Rock, Arkansas, Spojené státy, 72205
- University of Arkansas for Medical Sciences
-
Kontakt:
- Heather Moody
- Telefonní číslo: 501-526-4333
- E-mail: HLMoody@uams.edu
-
-
California
-
Palo Alto, California, Spojené státy, 94304
- Stanford University
-
Kontakt:
- Guillermina Ferrea
- Telefonní číslo: (650) 457 7704
- E-mail: gferrea@stanford.edu
-
Kontakt:
- Aleesha Jethwa
- Telefonní číslo: +44 7857 907762
- E-mail: Ajethwa1@stanford.edu
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Age ≥18
- Delivered a live infant within 5 days
- Severe maternal morbidity or infant admitted to NICU
- PCL-5 ≥28
- English-speaking
- Able to consent and participate
Exclusion Criteria:
- Active psychosis or mania
- Current suicidal crisis
- Current suicidal intent or plan
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Written Exposure Therapy (WET)
Participants will complete 5 writing sessions. One 50-minute session will be held in the hospital before discharge, followed by four 50-minute sessions by secure video once a week. Sessions are delivered by a trained study therapist under licensed clinician supervision. |
Participants will complete 5 writing sessions. One 50-minute session will be held in the hospital before discharge, followed by four 50-minute sessions by secure video once a week. Sessions are delivered by a trained study therapist under licensed clinician supervision. |
|
Experimentální: Capnometry-Guided Breathing Intervention (CGRI)
Participants will complete one 45-minute in-hospital training session using the device, which includes a tablet and breathing sensor. They will then practice guided breathing at home twice daily for about 17 minutes each time for 4 weeks, with weekly phone check-ins from study staff. |
Participants will complete one 45-minute in-hospital training session using the device, which includes a tablet and breathing sensor. They will then practice guided breathing at home twice daily for about 17 minutes each time for 4 weeks, with weekly phone check-ins from study staff. |
|
Žádný zásah: Postpartum Standard of Care
Participants will follow their current standard of care. |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Procento účastníků dokončujících terapii psanou expozicí (WET)
Časové okno: Od výchozího stavu do 6. týdne
|
Od výchozího stavu do 6. týdne
|
|
|
Procentuální adherence k psané expoziční terapii (WET)
Časové okno: Základní stav do 6. týdne
|
Základní stav do 6. týdne
|
|
|
Procento účastníků dokončujících intervenci dýchání s kapnometrickým vedením (CGRI)
Časové okno: Od výchozí hodnoty do 6. týdne
|
Od výchozí hodnoty do 6. týdne
|
|
|
Procentuální adherence k intervenci dýchání řízené kapnometrií (CGRI)
Časové okno: Základní stav do 6. týdne
|
Základní stav do 6. týdne
|
|
|
Percentage of participants initiating assigned treatment
Časové okno: Baseline (up to 2 weeks)
|
Proportion of participants who begin their assigned intervention (≥1 session for WET; completion of initial training for CGRI) |
Baseline (up to 2 weeks)
|
|
Participant Satisfaction Scale Score using Client Satisfaction Questionnaire (CSQ-8)
Časové okno: Week 5
|
Participant satisfaction measured using the CSQ-8 questionaire, an 8-item scale. (Scale score 8 - 32. Higher scores represent greater satisfaction with treatment.) |
Week 5
|
|
Treatment credibility using the Opinion About Treatment (OAT) form
Časové okno: Week 5
|
Participant perceptions of treatment credibility will be measured using the OAT form. (Scale score 3 - 27. Higher scores represent greater perceived credibility of the intervention.) |
Week 5
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Change from baseline in PTSD Checklist for DSM-5 (PCL-5) Scale Score
Časové okno: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 12
|
Change in PTSD symptoms during past week measured by the PTSD Checklist for DSM-5 (PCL-5), a 20-item self-report measure. (Score range 0 - 80, higher scores indicating greater severity of PTSD symptoms.). |
Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 12
|
|
Change from baseline in Edinburgh Postnatal Depression Scale (EPDS) Scale Score
Časové okno: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 12
|
Participants complete the EPDS questionnaire, a 10-item scale assessing postpartum depressive symptoms over the past 7 days. (Score range 0 - 30, higher scores represents greater symptom severity.) |
Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 12
|
|
Change from baseline in Whole Person Health Index (WPHI) Scale Score
Časové okno: Baseline, Week 3, Week 6, Week 12
|
Participants complete WHPI questionaire, a 9 item scale assessing global health and functioning. (Score range 9 - 81, higher scores represent better health). |
Baseline, Week 3, Week 6, Week 12
|
|
Change from baseline in Generalized Anxiety Disorder Questionaire (GAD-7)
Časové okno: Baseline, Week 3, Week 6, Week 12
|
Participants complete the GAD-7, a 7-item scale assessing anxiety symptoms over 2 weeks. (Score range 0 - 21, higher scores represent greater anxiety severity.) |
Baseline, Week 3, Week 6, Week 12
|
|
Change from baseline in Maternal-infant bonding (MIBS) Scale Score
Časové okno: Baseline, Week 3, Week 6, Week 12
|
Participants complete the MIBS questionaire, an 8 item measure of bonding difficulties over the past few weeks (Score range 0 - 24, higher scores represent greater bonding impairment). |
Baseline, Week 3, Week 6, Week 12
|
|
Change from baseline in STanford Obstetric Recovery checKlist (STORK) scale score
Časové okno: Baseline, Week 3, Week 6, Week 12
|
Participants complete the STORK questionnaire, a 47-item scale assessing postpartum recovery over the past 7 days. (Score range 0 - 188, higher score represents a greater degree of recovery) |
Baseline, Week 3, Week 6, Week 12
|
|
Change from baseline in Breastfeeding Self-Efficacy Scale-Short Form (BFSES-SF)
Časové okno: Baseline, Week 3, Week 6, Week 12
|
Participants complete the BFSES-SF, a 14-item measure of breastfeeding self-efficacy (Score range 14 - 70, higher scores indicate greater breastfeeding confidence.) |
Baseline, Week 3, Week 6, Week 12
|
|
Percentage of participants completing hair sample collection at Baseline and Week 6
Časové okno: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. |
Baseline, Week 6
|
|
Change in hair cortisol concentration between Baseline and Week 6
Časové okno: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair cortisol concentration from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair cortisone concentration between Baseline and Week 6
Časové okno: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair cortisone concentration from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair testosterone concentration between Baseline and Week 6
Časové okno: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair testosterone concentration from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair progesterone concentration between Baseline and Week 6
Časové okno: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair progesterone concentration from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair corticosterone concentration between Baseline and Week 6
Časové okno: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair corticosterone concentration from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair dehydroepiandrosterone (DHEA) concentration between Baseline and Week 6
Časové okno: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair dehydroepiandrosterone (DHEA) concentration values from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair androstenedione concentration between Baseline and Week 6
Časové okno: Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair androstenedione concentration from Baseline to Week 6 |
Baseline, Week 6
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Pervez Sultan, Stanford University
- Vrchní vyšetřovatel: Debra Kaysen, Stanford University
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 80498-2
- R01AT013866-01 (Grant/smlouva NIH USA)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
Časový rámec sdílení IPD
Beginning 9 months and ending 36 months following article publication.
Kritéria přístupu pro sdílení IPD
Wish whom? Investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose. For what types of analysis? For individual participant data meta-analysis By what mechanism will data be made available? Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata. Information regarding submitting proposals and accessing data may be found at (Link to be provided).
Typ podpůrných informací pro sdílení IPD
- PROTOKOL STUDY
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .